CytomX Therapeutics
CTMX
119 hedge funds and large institutions have $143M invested in CytomX Therapeutics in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 14 closing their positions.
85% more call options, than puts
Call options by funds: $63K | Put options by funds: $34K
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
8% more funds holding
Funds holding: 110 → 119 (+9)
1.53% less ownership
Funds ownership: 83.6% → 82.07% (-1.5%)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
39% less capital invested
Capital invested by funds: $236M → $143M (-$93.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.68M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$4.96M |
| 3 |
Millennium Management
New York
|
+$3.76M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.82M |
| 5 |
Renaissance Technologies
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.42M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.92M |
| 3 |
O
OrbiMed
New York
|
-$4.18M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.69M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$1.55M |
CTMX Hedge Fund Activity: Q1 2022 in Review
119 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2022, worth a combined $143M — down 39% from $236M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CTMX positions and 14 closed out — a net gain of 9 holders — while 33 added to existing stakes and 42 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $7.68M. The largest seller was Point72 Asset Management, cutting an estimated $7.42M.
- 119 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2022, up from 110 in Q4 2021.
- Funds reported $143M of CytomX Therapeutics stock for Q1 2022, down 39% quarter-over-quarter.
- 23 funds opened new CytomX Therapeutics positions in Q1 2022 and 14 closed out, a net change of +9 holders.
- The largest CytomX Therapeutics buyer in Q1 2022 was Adage Capital Partners, an estimated $7.68M added.
- The largest CytomX Therapeutics seller in Q1 2022 was Point72 Asset Management, an estimated $7.42M sold.
Based on aggregated 13F filings for Q1 2022.